Skip to main content
SpringerLink
Log in

A phase II study of carboplatin and vincristine in previously treated patients with small-cell lung cancer

  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

A total of 28 previously treated patients with small-cell lung cancer were treated at relapse with 400 mg/m2 carboplatin and 2 mg vincristine on days 1 and 8, every 4 weeks. Ten partial responses (PRs) (37%) but no complete responses (CRs) were seen. Median survival after the start of second-line treatment was 120 days (range, 39–503 days). Toxicity of this regimen was moderate, including WHO grade 3/4 myelosuppression in 26% of courses (n=66). Eight PRs were seen in a subgroup of 22 patients who relapsed <3 months after firstline treatment. The responses seen in this group of patients may be due to the absence of cross-resistance between the regimens used.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bishop JF, Raghavan D, Stuart-Harris R, Morstyn G, Aroney R, Kefford R, Yuen K, Lee J, Giamoutsous P, Olver JN, Zalcberg J, Ball D, Bull C, Fox R (1987) Carboplatin (CBDCA, JM8) and VP 16-213 in previously untreated patients with small cell lung cancer. J Clin Oncol 5: 1574–1578

    Google Scholar 

  2. Calvert AH, Harland SJ, Newell DR, Siddik ZH, Jones AC, McElwain TJ, Raju S, Wiltshaw E, Smith IE, Baker JM, Peckham MJ, Harrap KR (1982) Early clinical studies withcis-diammine-1,1-cyclobutane dicarboxylate platinum (II). Cancer Chemother Pharmacol 9: 140–147

    Google Scholar 

  3. Curt GA, Grygiel JJ, Corden BJ (1983) A phase I and pharmacokinetic study of diammine cyclobutane-dicarboxylate platinum (NSC 241240). Cancer Res 43: 4470–4473

    Google Scholar 

  4. Dombernowsky P, Sorensen S, Aisner J, Hansen HH (1979)cis-Dichlorodiammineplatinum(II) in small cell anaplastic bronchogenic carcinoma: a phase II study. Cancer Treat Rep 63: 543–545

    Google Scholar 

  5. EORTC Lung Cancer Cooperative Group (1988) Evaluation of non-cross resistance of carboplatin-containing regimens with cyclophosphamide, doxorubicin and etoposide in patients with small cell lung cancer. EORTC study 08862, abstract 6. 1. 63, Interlaken

  6. Foster BJ, Clagget-Carr K, Leyland Jones B, Hoth D (1985) Results of NCI-sponsored phase I trials with carboplatin. Cancer Treat Rev 12 [Suppl A]: 43–49

    Google Scholar 

  7. Giaccone G, Ferrati P, Donadio M, Testore F, Calciati A (1987) Reinduction chemotherapy in small cell lung cancer. Eur J Cancer Clin Oncol 23: 1697–1699

    Google Scholar 

  8. Ianuzzi MC, Scoggin CH (1986) Small cell lung cancer, state of the art. Am Rev Resp Dis 134: 593–608

    Google Scholar 

  9. Jacobs RH, Bitran JD, Deutsch M, Hoffman PC, Sinkule J, Purl S, Golomb HM (1987) Phase II study of carboplatin in previously untreated patients with metastatic small cell lung carcinoma. Cancer Treat Rep 71: 311–312

    Google Scholar 

  10. Johnson BE, Ihde DC, Bunn PA (1985) Patients with small cell lung cancer treated with combination chemotherapy with or without irradiation. Ann Intern Med 103: 430–438

    Google Scholar 

  11. Johnson DH, Greco FA (1987) Treatment of small cell lung cancer: another study on alternating chemotherapy. Eur J Cancer Clin Oncol 23: 1577–1579

    Google Scholar 

  12. Livingston RB, Stephens RL, Bonnet JD (1984) Long term survival and toxicity in small cell lung cancer. Am J Med 77: 415–417

    Google Scholar 

  13. Postmus PE, Berendsen HH, Zandwijk N van, Splinter TAW, Burghouts JThM, Bakker W, for the EORTC Lung Cancer Cooperative Group (1987) Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. Eur J Cancer Clin Oncol 23: 1409–1411

    Google Scholar 

  14. Postmus PE, Kirkpatrick A, Dalesio O, Palmen FJ, Carney DN, Festen J, Vendrik C, Roozendaal K, Burghouts J, Planting E, Quoix E, Splinter TAW, McVie JG (1988) Two carboplatin-containing regimens for small cell lung cancer: preliminary results of a randomized phase II trial. Cancer Treat Rev 15 [Suppl B]: 41–44

    Google Scholar 

  15. Santoro A, Bonadonna G, Bonfante V, Valagussa P (1982) Alternating drug combinations in the treatment of advanced Hodgkin's disease. New Engl J Med 306: 770–775

    Google Scholar 

  16. Smith IE, Perrent V (1987) Carboplatin, VP-16 and ifosfamide intensive chemotherapy for small cell lung carcinoma. Proc ASCO 6: 179

    Google Scholar 

  17. Smith IE, Harland SJ, Robinson BA, Evans BD, Goodhart LC, Calvert AH, Yarnold J, Glees JP, Baker J, Ford HT (1985) Carboplatin: a very active new cisplatin analog in the treatment of small cell lung cancer. Cancer Treat Rep 69: 43–46

    Google Scholar 

  18. Smith IE, Evans BD, Gore ME, Vincent MD, Repetto L, Yarnold JR, Ford HT (1987) Carboplatin (Paraplatin, JM8) and etoposide (VP-16) as first line combination therapy for small cell lung cancer. J Clin Oncol 5: 185–189

    Google Scholar 

  19. Van Glabbeke M, Renard J, Pinedo HM, Cavalli F, Vermorken J, Cessa C, Abele R, Clavel M, Monfardini S (1988) Iproplatin and carboplatin induced toxicities: overview of phase II clinical trials conducted by the EORTC Early Clinical Trials Cooperative Group. Eur J Cancer Clin Oncol 24: 255–262

    Google Scholar 

  20. Vincent M, Evans B, Smith IE (1988) First line chemotherapy rechallenge after relapse in small cell lung cancer. Cancer Chemother Pharmacol 21: 45–48

    Google Scholar 

  21. WHO (1978) Handbook for reporting results of cancer treatment. WHO Offset Publication 48. Nijhoff, Den Haag

    Google Scholar 

  22. Winkler CF, Batist G, Veach SR, Eddy JL, Mulshine JL, Ihde DC (1985) Phase II study ofcis-diammine-1,1 cyclobutane diacarboxylate platinum(II) (CBDCA, NSC 241240) in non small cell and small cell lung cancer. Proc ASCO 4: 186

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pulmonary Diseases, University Hospital, Oostersingel 59, 9713 EZ, Groningen, The Netherlands

    Egbert F. Smit, Henk H. Berendsen & Pieter E. Postmus

  2. Department of Internal Medicine, Division Medical Oncology, University Hospital, Groningen, The Netherlands

    Egbert F. Smit, Elisabeth G. E. de Vries & Nanno H. Mulder

Authors
  1. Egbert F. Smit
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Henk H. Berendsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Elisabeth G. E. de Vries
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nanno H. Mulder
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Pieter E. Postmus
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Smit, E.F., Berendsen, H.H., de Vries, E.G.E. et al. A phase II study of carboplatin and vincristine in previously treated patients with small-cell lung cancer. Cancer Chemother. Pharmacol. 25, 202–204 (1989). https://doi.org/10.1007/BF00689583

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00689583

Keywords

Search

Navigation